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Background: Bilateral sagittal split ramus osteotomy (BSSRO) is a common orthognatic surgical procedure. Sensory
disturbances in the inferior alveolar nerve, including hypoesthesia and dysesthesia, are frequently observed after
BSSRO, even without distinct nerve injury. The mechanisms that underlie individual differences in the vulnerability
to sensory disturbances have not yet been elucidated.
Methods: The present study investigated the relationships between genetic polymorphisms and the vulnerability
to sensory disturbances after BSSRO in a genome-wide association study (GWAS). A total of 304 and 303 patients
who underwent BSSRO were included in the analyses of hypoesthesia and dysesthesia, respectively. Hypoesthesia
was evaluated using the tactile test 1 week after surgery. Dysesthesia was evaluated by interview 4 weeks after
surgery. Whole-genome genotyping was conducted using Illumina BeadChips including approximately 300,000
polymorphism markers.
Results: Hypoesthesia and dysesthesia occurred in 51 (16.8%) and 149 (49.2%) subjects, respectively. Significant
associations were not observed between the clinical data (i.e., age, sex, body weight, body height, loss of blood
volume, migration length of bone fragments, nerve exposure, duration of anesthesia, and duration of surgery) and
the frequencies of hypoesthesia and dysesthesia. Significant associations were found between hypoesthesia and the
rs502281 polymorphism (recessive model: combined χ2 = 24.72, nominal P = 6.633 × 10-7), between hypoesthesia
and the rs2063640 polymorphism (recessive model: combined χ2 = 23.07, nominal P = 1.563 × 10-6), and between
dysesthesia and the nonsynonymous rs2677879 polymorphism (trend model: combined χ2 = 16.56, nominal
P = 4.722 × 10-5; dominant model: combined χ2 = 16.31, nominal P = 5.369 × 10-5). The rs502281 and rs2063640
polymorphisms were located in the flanking region of the ARID1B and ZPLD1 genes on chromosomes 6 and 3,
whose official names are “AT rich interactive domain 1B (SWI1-like)” and “zona pellucida-like domain containing 1”,
respectively. The rs2677879 polymorphism is located in the METTL4 gene on chromosome 18, whose official name
is “methyltransferase like 4”.
Conclusions: The GWAS of sensory disturbances after BSSRO revealed associations between genetic
polymorphisms located in the flanking region of the ARID1B and ZPLD1 genes and hypoesthesia and between a
nonsynonymous genetic polymorphism in the METTL4 gene and dysesthesia.
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Table 1 Expression frequency of hypoesthesia and
dysesthesia after BSSRO
Normal Abnormal
Hypoesthesia 253 (83.2%) 51 (16.8%)
Dysesthesia 154 (50.8%) 149 (49.2%)
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Neuropathic pain in the orofacial region is a clinical
manifestation of trigeminal nerve injury following oral
surgery. Neuropathic pain subsequent to nerve damage
at a central or peripheral site remains a major problem
for both patients and clinicians because the pain is usu-
ally extremely intense and often refractory to various
conventional pain therapies. Moreover, remarkable indi-
vidual differences in the vulnerability to neuropathic
pain exist. Many studies have been performed to reveal
the mechanisms that underlie neuropathic pain, but only
a few genetic studies have focused on neuropathic pain
[1,2], possibly because individual differences across pa-
tients with neuropathic pain are usually affected by vari-
ous factors other than genetic factors.
Sensory disturbances, including hypoesthesia and dy-
sesthesia, often appear as a prodromal symptom of
neuropathic pain. Sensory disturbances or neuropathic
pain in the inferior alveolar nerve are inevitably caused
by a primary lesion or dysfunction of the nerve. The
symptoms, however, are subject to individual differences
in daily clinical practice and may be related to genetic
factors. Bilateral sagittal split ramus osteotomy (BSSRO)
is commonly conducted to correct jaw deformities, such
as mandibular prognathism. Sensory disturbances in the
inferior alveolar nerve, including hypoesthesia and
dysesthesia, are frequently observed in the lower lip and
mental area after BSSRO, even without distinct nerve in-
jury. Symptom frequency 1 or 2 weeks after BSSRO is
reported in 25-56% of patients [3-5]. Considering that al-
most all patients who undergo BSSRO are young and
healthy and the degree of surgical invasiveness, surgical
site, and surgical procedures are highly consistent across
cases, environmental factors appear to have relatively little
impact on individual differences in the vulnerability to
sensory disturbances or neuropathic pain after BSSRO.
Innovative techniques have been used to investigate
the genetic factors related to various human traits. A
wide array of information on the entire human genome
has accumulated, and the results of genome-wide associ-
ation studies (GWASs) have been reported [6,7]. A
marked increase in the rate of discovery of genes associ-
ated with various diseases has also occurred [8].
The present GWAS investigated the relationships be-
tween genetic polymorphisms and the vulnerability to
sensory disturbances after BSSRO.
Results
Clinical data overview and SNP data management for
GWAS
Hypoesthesia and dysesthesia occurred in 51 (16.8%)
and 149 (49.2%) of the 304 and 303 patients, respectively
(Table 1). Logistic regression analysis revealed no signifi-
cant associations between the clinical data and frequencyof hypoesthesia or dysesthesia after BSSRO (data not
shown).
After filtering the markers by genotype call frequency,
“Cluster sep”, and minor allele frequencies in the first
quality control assessment of the genotyping data,
243,501 markers were selected. These merged genotype
data from five different BeadChips consisted of single nu-
cleotide polymorphism (SNP) markers on the autosome
or sex chromosome, and no mitochondrial marker was in-
cluded. Furthermore, 272 markers were excluded based
on the Hardy-Weinberg equilibrium test (P ≤ 2 × 10-7).
As a result, a total of 243,229 SNP markers (including
4,822 nonsynonymous SNPs) were selected for the sub-
sequent association study (Additional file 1: Figure S1
and Additional file 2: Figure S2).
GWAS identified several loci associated with sensory
disturbances in the inferior alveolar nerve after BSSRO
The GWAS was performed to detect any signals associ-
ated with hypoesthesia or dysesthesia after BSSRO as
three-stage analyses for two independent patterns: (1) a
normal GWAS procedure that targeted all of the SNPs
that were available (Additional file 1: Figure S1) and (2) a
GWAS procedure that targeted only nonsynonymous
SNPs that tended to affect the function of the protein
encoded by the relevant gene (Additional file 2: Figure S2).
In the first analysis that targeted all of the SNPs, six,
five, and 22 SNPs were selected as the top candidates as-
sociated with hypoesthesia for the trend, dominant, and
recessive models for each minor allele, respectively, after
the final stage (Table 2). Seven, four, and nine SNPs were
selected as the top candidates associated with dysesthesia
for the trend, dominant, and recessive models for each
minor allele, respectively, after the final stage (Table 3).
Among these, two SNPs, rs502281 and rs2063640,
showed significant associations with hypoesthesia after
the final stage in the recessive model (rs502281: χ2 =
16.44, Q = 0.0196; rs2063640: χ2 = 14.38, Q = 0.0291;
Table 2). None of the SNPs showed significant associa-
tions with dysesthesia after the final stage in any of the
models (Table 3).
In the second analysis that targeted nonsynonymous
SNPs, four, three, and 14 SNPs were selected as the top
candidates associated with hypoesthesia for the trend,
dominant, and recessive models for each minor allele,
respectively, after the second stage (Table 4). Three, five,
and two SNPs were selected as the top candidates
Table 2 Top candidate SNPs selected after final stage analysis in 3-stage GWAS targeting all SNPs (hypoesthesia)
Model Rank SNP CHR Position 1st stage 2nd stage Final stage Combined Genotype Related gene
X2 P X2 P X2 P Q X2 P Abnormal Normal
Trend 1 rs7228266 18 40874531 4.377 0.0364 6.005 0.0143 9.102 0.0026 0.567 19.15 1.21E-05 7/28/16 8/92/153 SETBP1
Trend 2 rs6537883 1 110206794 5.962 0.0146 5.917 0.015 6.385 0.0115 0.6855 18.13 2.06E-05 2/6/43 35/93/121 CSF1
Trend 3 rs9474312 6 52706460 5.95 0.0147 6.026 0.0141 5.866 0.0154 0.6855 18.03 2.18E-05 9/24/18 11/84/157 LOC730152
Trend 4 rs1870761 11 122356773 4.184 0.0408 7.947 0.0048 4.011 0.0452 0.7696 15.87 6.79E-05 0/8/42 16/100/134 BSX
Trend 5 rs139131 22 42912379 7.103 0.0077 4.071 0.0436 4.38 0.0364 0.7696 15.6 7.81E-05 0/7/44 10/100/143 PARVG
Trend 6 rs2295343 20 3683601 4.657 0.0309 4.81 0.0283 6.327 0.0119 0.6855 15.11 0.000101 0/6/45 10/93/150 C20orf27
Dominant 1 rs6537883 1 110206794 7.505 0.0062 5.984 0.0144 8.612 0.0033 0.4897 21.79 3.04E-06 2/6/43 35/93/121 CSF1
Dominant 2 rs139131 22 42912379 7.32 0.0068 4.126 0.0422 4.264 0.0389 0.763 15.87 6.78E-05 0/7/44 10/100/143 PARVG
Dominant 3 rs2295343 20 3683601 4.574 0.0325 5.147 0.0233 6.631 0.01 0.5288 15.46 8.41E-05 0/6/45 10/93/150 C20orf27
Dominant 4 rs10502849 18 40866089 5.286 0.0215 3.933 0.0473 6.161 0.0131 0.5288 15.25 9.41E-05 11/28/11 20/101/1 SETBP1
Dominant 5 rs707816 6 13742961 4.586 0.0322 3.933 0.0473 5.075 0.0243 0.7257 13.08 0.000299 2/15/34 33/121/99 RANBP9
Recessive 1 rs2817461 6 156954704 8.06 0.0045 12.55 0.0004 12.53 0.0004 0.0521 30.33 3.64E-08 9/42 3/250 ARID1B
Recessive 2 rs502281 6 156910640 3.991 0.0458 6.935 0.0085 16.44 5E-05 0.0196* 24.72 6.63E-07 7/9/35 2/71/180 ARID1B
Recessive 3 rs2063640 3 103685735 6.085 0.0136 4.932 0.0264 14.38 0.0001 0.0291* 23.07 1.56E-06 15/11/25 17/110/125 ZPLD1
Recessive 4 rs13236243 7 17284837 10.43 0.0012 6.658 0.0099 4.14 0.0419 0.7421 21.14 4.28E-06 16/16/19 21/121/111 LOC729939
Recessive 5 rs1054611 12 10061428 6.1 0.0135 4.344 0.0371 11.07 0.0009 0.0775 20.61 5.64E-06 10/16/25 8/84/161 CLEC12B
Recessive 6 rs6833812 4 5161041 3.991 0.0458 12.25 0.0005 5.428 0.0198 0.4066 20.11 7.32E-06 4/9/38 0/57/196 STK32B
Recessive 7 rs1059513 12 55775976 8.06 0.0045 6.062 0.0138 5.428 0.0198 0.4066 20.11 7.32E-06 4/8/39 0/32/221 STAT6
Recessive 8 rs1998930 6 156945948 5.157 0.0232 11.29 0.0008 6.002 0.0143 0.4066 19.52 9.94E-06 22/21/8 40/130/83 ARID1B
Recessive 9 rs4235662 5 84203580 7.754 0.0054 6.062 0.0138 5.428 0.0198 0.4066 19.42 1.05E-05 5/18/28 1/96/156 EDIL3
Recessive 10 rs3804357 4 102221146 5.165 0.0231 6.551 0.0105 10.84 0.001 0.0775 19.3 1.12E-05 8/16/27 5/102/144 PPP3CA
Recessive 11 rs4732828 8 28050160 3.991 0.0458 5.99 0.0144 5.791 0.0161 0.4066 15.27 9.31E-05 3/5/42 0/20/232 ELP3
Recessive 12 rs4658506 1 240012540 3.991 0.0458 6.062 0.0138 5.428 0.0198 0.4066 15.03 0.000106 3/11/37 0/67/186 WDR64
Recessive 13 rs2868145 19 37738954 3.991 0.0458 6.062 0.0138 5.428 0.0198 0.4066 15.03 0.000106 3/10/38 0/42/211 PDCD5
Recessive 14 rs1564492 15 71720771 3.991 0.0458 6.062 0.0138 5.428 0.0198 0.4066 15.03 0.000106 3/10/38 0/37/216 NPTN
Recessive 15 rs1072056 5 110532014 3.991 0.0458 6.062 0.0138 5.428 0.0198 0.4066 15.03 0.000106 3/6/42 0/59/194 WDR36
Recessive 16 rs10512369 9 109805180 3.991 0.0458 6.062 0.0138 5.428 0.0198 0.4066 15.03 0.000106 3/7/41 0/25/228 LOC392382
Recessive 17 rs10841907 12 21942563 5.185 0.0228 5.026 0.025 4.956 0.026 0.5072 14.95 0.00011 11/18/21 14/104/135 ABCC9
Recessive 18 rs9942977 9 108422182 3.895 0.0484 6.062 0.0138 5.428 0.0198 0.4066 14.91 0.000113 3/5/43 0/28/223 LOC644620
















Table 2 Top candidate SNPs selected after final stage analysis in 3-stage GWAS targeting all SNPs (hypoesthesia) (Continued)
Recessive 20 rs13110230 4 178153868 3.991 0.0458 6.062 0.0138 6.074 0.0137 0.4066 14.55 0.000136 4/9/38 1/48/204 VEGFC
Recessive 21 rs1960997 11 97149034 3.991 0.0458 4.344 0.0371 5.675 0.0172 0.4066 11.66 0.000638 6/19/26 5/104/144 CNTN5
Recessive 22 rs9535720 13 51092945 3.999 0.0455 3.907 0.0481 4.141 0.0419 0.7421 11.61 0.000656 6/19/26 38/140/75 WDFY2
















Table 3 Top candidate SNPs selected after final stage analysis in 3-stage GWAS targeting all SNPs (dysesthesia)
Model Rank SNP CHR Position 1st stage 2nd stage Final stage Combined Genotype Related gene
X2 P X2 P X2 P Q X2 P Abnormal Normal
Trend 1 rs6829274 4 36167210 4.852 0.0276 6.571 0.0104 5.444 0.0196 0.6536 16.91 3.91E-05 12/65/72 29/83/42 FLJ16686
Trend 2 rs945877 1 197785628 6.571 0.0104 4.92 0.0266 4.828 0.028 0.6536 16.84 4.07E-05 45/74/30 24/69/61 LOC647202
Trend 3 rs2677879 18 2537500 4.078 0.0435 6.071 0.0137 6.585 0.010 0.6536 16.56 4.72E-05 13/51/84 28/73/51 METTL4
Trend 4 rs7825569 8 70057575 5.909 0.0151 6.756 0.0093 3.846 0.0499 0.7411 15.31 9.14E-05 42/77/30 21/76/57 C8orf34
Trend 5 rs1064108 14 64470018 4.777 0.0288 5.124 0.0236 4.78 0.0288 0.653 15.01 0.000107 31/63/55 8/66/80 CHURC1
Trend 6 rs11817730 10 9934850 4.651 0.031 3.85 0.0498 6.73 0.0095 0.6536 14.48 14.48 1/13/135 4/37/113 C10orf65
Trend 7 rs12603925 17 14929712 4.248 0.0393 4.005 0.0454 4.268 0.0388 0.7411 12.29 0.000456 20/66/62 39/74/38 LOC44178
Dominant 1 rs2210585 20 10077600 7.653 0.0057 4.356 0.0369 6.442 0.0111 0.816 17.94 2.28E-05 24/90/35 15/67/72 SNAP25
Dominant 2 rs2677879 18 2537500 3.905 0.0481 5.79 0.0161 6.669 0.0098 0.816 16.31 5.37E-05 13/51/84 28/73/51 METTL4
Dominant 3 rs10805209 4 8600745 6.282 0.0122 4.376 0.0365 4.474 0.0344 0.816 13.72 0.000212 28/68/53 47/81/26 GPR78
Dominant 4 rs6477523 9 108304897 4.762 0.0291 4.356 0.0369 4.151 0.0416 0.816 13.59 0.000228 25/89/35 32/55/67 LOC644620
Recessive 1 rs1567375 11 119007687 5.911 0.0151 9.524 0.002 4.67 0.0307 0.4279 19 1.31E-05 35/67/47 9/81/64 PVRL1✝
Recessive 2 rs4902304 14 64189429 9.896 0.0017 4.376 0.0365 4.149 0.0417 0.4279 17.32 3.15E-05 10/79/60 37/67/50 PLEKHG3
Recessive 3 rs6982411 8 135076849 6.562 0.0104 5.275 0.0216 3.977 0.0461 0.4279 15.69 7.46E-05 17/52/80 1/58/95 LOC729395
Recessive 4 rs730545 5 180446073 4.072 0.0436 4.057 0.044 7.119 0.0076 0.3997 15.55 8.05E-05 18/96/34 47/64/41 BTNL9
Recessive 5 rs10837504 11 40775682 4.595 0.0321 3.852 0.0497 5.934 0.0149 0.4279 14.19 0.000165 2/70/77 19/59/76 LRRC4C
Recessive 6 rs7551844 1 53833921 5.176 0.0229 4.631 0.0314 3.916 0.0478 0.4279 13.7 0.000214 20/89/40 48/70/36 GLIS1
Recessive 7 rs236008 16 6981244 4.062 0.0439 4.174 0.0411 5.273 0.0217 0.4279 13.43 0.000248 15/49/85 1/63/90 HYDIN
Recessive 8 rs2838271 21 43586302 4.595 0.0321 4.174 0.0411 4.362 0.0368 0.427 13.15 0.000288 2/58/89 18/56/80 LOC727743
Recessive 9 rs10497603 2 183044713 4.594 0.0321 4.019 0.045 3.915 0.0479 0.4279 12.08 0.000511 16/55/78 2/67/85 PDE1A
















Table 4 Top candidate SNPs selected after second stage analysis in 3-stage GWAS targeting nonsynonymous SNPs (hypoesthesia)
Model Rank SNP CHR Position 1st stage 2nd stage Final stage Combined Genotype Related
geneX2 P X2 P X2 P Q X2 P Abnormal Normal
Trend 1 rs2839227 21 46610952 5.771 0.0163 8.95 0.0028 0.4962 0.4812 0.7406 11.63 0.00065 7/29/15 19/88/143 PCNT
Trend 2 rs4074536 1 116112490 4.724 0.0298 3.904 0.0482 0.1467 0.7017 0.7406 7.338 0.006753 6/24/21 58/135/60 CASQ2
Trend 3 rs2296351 13 51607939 4.131 0.0421 4.244 0.0394 0.1096 0.7406 0.7406 6.061 0.01382 2/19/30 5/56/192 NEK3
Trend 4 rs1339847 1 246105917 4.141 0.0419 4.938 0.0263 0.7541 0.3852 0.7406 3.974 0.04622 6/11/34 4/65/184 TRIM58
Dominant 1 rs2228576 12 6327323 7.136 0.0076 4.904 0.0268 3.013 0.0826 0.2477 15.42 8.6E-05 9/35/6 37/108/102 SCNN1A
Dominant 2 rs2839227 21 46610952 7.313 0.0068 5.538 0.0186 1.604 0.2053 0.308 13.12 0.000293 7/29/15 19/88/143 PCNT
Dominant 3 rs140685 15 24771205 4.14 0.0419 7.867 0.005 0.7902 0.374 0.374 10.14 0.001451 4/13/34 21/125/107 GABRA5
Recessive 1 rs1339847 1 246105917 11.66 0.0006 6.062 0.0138 0.2731 0.6013 0.6747 13.84 0.000199 6/11/34 4/65/184 TRIM58
Recessive 2 rs6733871 2 80383467 5.553 0.0185 6.125 0.0133 2.058 0.1514 0.5334 12.24 0.000469 18/18/15 37/128/88 LRRTM1
Recessive 3 rs913588 9 7164673 4.14 0.0419 6.062 0.0138 1.816 0.1778 0.5334 10.91 0.000956 4/11/36 2/55/196 JMJD2C
Recessive 4 rs1079109 1 159761664 3.951 0.0469 6.529 0.0106 NA NA NA 10.16 0.001432 3/8/38 1/93/156 HSPA6
Recessive 5 rs11088981 21 43694578 3.991 0.0458 5.919 0.015 1.816 0.1778 0.5334 9.754 0.00179 3/14/34 1/55/195 C21orf125
Recessive 6 rs3779234 7 35676367 7.646 0.0057 8.992 0.0027 0.9782 0.3226 0.6747 9.313 0.002276 8/14/29 11/116/126 HERPUD2
Recessive 7 rs12831803 12 124127104 3.991 0.0458 4.344 0.0371 1.816 0.1778 0.5334 8.362 0.003831 4/11/36 3/81/169 AACS
Recessive 8 rs2032887 19 8027360 4.14 0.0419 4.344 0.0371 NA NA NA 8.362 0.003831 4/13/34 3/61/189 CCL25
Recessive 9 rs12609976 19 60279634 3.991 0.0458 6.062 0.0138 0.7278 0.3936 0.6747 6.803 0.009103 3/9/39 2/54/197 EPS8L1
Recessive 10 rs7173826 15 65315428 5.157 0.0232 5.143 0.0234 0.4055 0.5243 0.6747 5.549 0.01849 12/15/23 29/124/99 FLJ11506
Recessive 11 rs2070180 3 122834028 3.991 0.0458 5.99 0.0144 0.1762 0.6747 0.6747 5.508 0.01893 2/5/43 1/47/204 HCLS1
Recessive 12 rs10907376 1 221634426 3.991 0.0458 4.344 0.0371 0.1879 0.6647 0.6747 4.839 0.02782 3/11/37 3/50/200 C1orf65
Recessive 13 rs6667999 1 223600307 3.999 0.0455 4.455 0.0348 0.4701 0.493 0.6747 3.921 0.04769 15/26/10 44/136/73 DNAH14
Recessive 14 rs316019 6 160590272 3.991 0.0458 6.935 0.0085 0.582 0.4455 0.6747 3.467 0.0626 3/10/38 4/54/194 SLC22A2
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http://www.molecularpain.com/content/9/1/34associated with dysesthesia, respectively, after the second
stage (Table 5). Among these, none of the SNPs showed
significant associations with hypoesthesia after the final
stage in any of the models (Table 4). One SNP, rs2677879,
showed significant associations with dysesthesia after the
final stage in the trend and dominant models (trend
model: χ2 = 6.585, Q = 0.0309; dominant model: χ2 =
6.669, Q = 0.0491; Table 5). Statistical power analyses re-
vealed that the expected power (1 minus type II error
probability) was only 19.5% and 15.1% for the Cohen’s
conventional “small” effect size of 0.10 [9] and 90.8% and
84.6% for the medium effect size of 0.30, with a total of
120 valid samples in each stage. The degrees of freedom
were set at 1 and 2, respectively, for the nominal type I
error probability of 0.05. The estimated effect sizes were
0.26 and 0.28 to achieve 80% power for this type I error
probability using our samples. The degrees of freedom
were set at 1 and 2, respectively.
Candidate loci revealed by the GWAS were located
around/within the gene regions of ARID1B, ZPLD1, and
METTL4
Figures 1 and 2 present the genome-wide associations
between polymorphism markers and the susceptibility to
hypoesthesia evaluated by the Semmes-Weinstein pres-
sure aesthesiometer test after BSSRO for all of the sam-
ples in each model for each chromosome. Significant
associations were found between hypoesthesia and the
rs502281 SNP (recessive model: combined χ2 = 24.72,
nominal P = 6.633 × 10-7; Table 2; Additional file 3:
Table S1) and rs2063640 SNP (recessive model: combined
χ2 = 23.07, nominal P = 1.563 × 10-6; Table 2; Additional
file 3: Table S2) and between dysesthesia and the
rs2677879 SNP (trend model: combined χ2 = 16.56, nom-
inal P = 4.722 × 10-5; dominant model: combined χ2 =
16.31, nominal P = 5.369 × 10-5; Table 5; Additional file 3:
Table S3) in two independent patterns of analyses with all
of the samples. According to the annotation information
supplied by the manufacturer of the whole-genome geno-
typing arrays (Illumina, San Diego, CA), the rs502281 and
rs2063640 SNPs are located within the gene flanking re-
gion of ARID1B and ZPLD1 on chromosomes 6 and 3
(Table 2; Figure 1), whose official names are “AT rich
interactive domain 1B (SWI1-like)” and “zona pellucida-
like domain containing 1”, respectively, based on the
National Center for Biotechnology Information database
[10]. The rs2677879 SNP is located within the gene region
of METTL4 on chromosome 18 (Table 5; Figure 2), whose
official name is “methyltransferase like 4”, based on the
same database.
Discussion
The present study explored genome-wide associations be-
tween common genetic variations and sensory disturbancesafter BSSRO. There are occasional reports in the literature
about the relationship between individual genetic polymor-
phisms and neuropathic pain [11,12]. One study investi-
gated the association between catechol-O-methyltransferase
gene polymorphisms and pain sensitivity and musculo-
skeletal pain attributed to temporomandibular disorders
[13]. Another study focused on the association between
HLA gene polymorphisms and postherpetic neuralgia,
also known as intractable chronic pain disorder [14]. Al-
though a GWAS was previously conducted in patients
with neuropathic pain induced by administration of pacli-
taxel for breast cancer [15], no other such studies have
been performed to determine the development of postop-
erative peripheral neuropathy. BSSRO is among the most
frequent surgical procedures in the area of oral surgery,
and its procedures are well standardized. Because patient
candidates for BSSRO are relatively healthy and young,
they are a good population for studies of postoperative
peripheral neuropathy. We conducted a GWAS to investi-
gate the onset of sensory disturbances after BSSRO.
The results of the present study showed that hy-
poesthesia and dysesthesia occurred in 16.8% (51 of 304)
and 49.2% (149 of 303) of the patients, respectively. Our
incidence rate for hypoesthesia tended to be lower than
previously reported incidences that ranged from 25% to
56% [3-5]. One reason for this may be the fact that
BSSRO is performed by a limited number of skilled sur-
geons at our hospital, although several other reasons
may explain the lower incidence of hypoesthesia. Hy-
poesthesia and dysesthesia are classified into vulnerabil-
ity of the peripheral nerve to external stress and
property of emergence of neuropathic pain following
nerve injury, respectively. Thereby, the candidate genes,
which were found in the present study, should be associ-
ated with these two aspects.
The GWAS identified ARID1B, ZPLD1, and METTL4
as candidates that may be associated with the onset of
sensory disturbances. The ARID1B gene, which is lo-
cated in 6q25.3, encodes a protein that is a member of
the ARID family of DNA-binding proteins and a subunit
of human SWI/SNF-related complexes. The SWI/SNF
complexes are known to use energy generated by an in-
tegral adenosine triphosphatase subunit to remodel chro-
matin. These complexes are involved in maintaining
normal cellular functions and restricting the access of
regulatory factors to nucleosomal DNA [16]. The ARID1B
gene has been suggested to be associated with the occur-
rence of Coffin-Siris syndrome [17], a multiple congenital
anomaly/mental retardation syndrome characterized by
mild to moderate mental retardation, moderate to severe
hypotonia, epilepsy, and congenital malformation, includ-
ing a coarse facial appearance and incompletely formed
fifth fingers and toes. Haploinsufficiency of the ARID1B
gene is speculated to be a common potential cause of
Table 5 Top candidate SNPs selected after second stage analysis in 3-stage GWAS targeting nonsynonymous SNPs (dysesthesia)
Model Rank SNP CHR Position 1st stage 2nd stage Final stage Combined Genotype Related
geneX2 P X2 P X2 P Q X2 P Abnormal Normal
Trend 1 rs2677879 18 2537500 4.078 0.0435 6.071 0.0137 6.585 0.0103 0.0309* 16.56 4.72E-05 13/51/84 28/73/51 METTL4
Trend 2 rs3803800 17 7403693 7.797 0.0052 4.983 0.0256 0.2319 0.6301 0.6301 7.157 0.007467 20/73/56 6/75/73 TNFSF13
Trend 3 rs3777722 6 167272094 7.531 0.0061 1.063 0.3025 1.063 0.3025 0.4538 4.367 0.03665 20/68/60 11/66/77 RNASET2
Dominant 1 rs2677879 18 2537500 3.905 0.0481 5.79 0.0161 6.669 0.0098 0.0491* 16.31 5.37E-05 13/51/84 28/73/51 METTL4
Dominant 2 rs1047406 8 22626880 7.581 0.0059 4.356 0.0369 0.4674 0.4942 0.4942 10.69 0.001078 10/52/87 13/80/61 PEBP4
Dominant 3 rs11205415 1 247087307 4.237 0.0396 4.381 0.0363 1.34 0.2471 0.4118 10.17 0.00143 23/68/58 28/92/34 LOC727776
Dominant 4 rs2240308 17 60985053 4.246 0.0393 5.061 0.0245 0.7561 0.3845 0.4806 8.659 0.003254 16/74/59 16/51/87 AXIN2
Dominant 5 rs3777722 6 167272094 4.439 0.0351 6.171 0.013 3.221 0.0727 0.1818 2.725 0.09881 20/68/60 11/66/77 RNASET2
Recessive 1 rs3803800 17 7403693 5.97 0.0146 6.008 0.0142 0.0048 0.9445 0.9445 8.762 0.003076 20/73/56 6/75/73 TNFSF13
Recessive 2 rs3213706 11 22837578 4.37 0.0366 7.551 0.006 0.1556 0.6932 0.9445 5.98 0.01447 8/73/68 21/58/75 LOC645581
















Figure 1 Genome-wide association for all samples between polymorphism markers and susceptibility to hypoesthesia evaluated by
the Semmes-Weinstein pressure aesthesiometer test after BSSRO in (A) trend, (B) dominant, and (C) recessive models. The data are
plotted as –log10 (P value) for each chromosome of 1-22 and X (from left to right).
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http://www.molecularpain.com/content/9/1/34intellectual disability and speech impairment. The nervous
system may be involved in the intractability and chronicity
of neuropathic pain [18,19], but it is unclear whetherARID1B is associated with pain mechanism. According to
the HapMap database [20], however, the rs2817461 and
rs502281 SNPs identified in the present study are located
Figure 2 Genome-wide association for all samples between polymorphism markers and susceptibility to dysesthesia after BSSRO in
(A) trend, (B) dominant, and (C) recessive models. The data are plotted as –log10 (P value) for each chromosome of 1-22 and X (from left to
right).
Kobayashi et al. Molecular Pain 2013, 9:34 Page 10 of 16
http://www.molecularpain.com/content/9/1/34upstream (approximately 200 kbp) from the ARID1B gene.
Further studies are needed to examine the effects of these
SNPs on ARID1B gene expression and function.The functions of ZPLD1 remain unclear, but one re-
port investigated the involvement of ZPLD1 in cerebral
cavernous malformations [21]. The ZPLD1 gene may be
Table 6 Clinical data
All patients (male, n = 114 ; female, n = 190)
Age (mean ± SEM) (range) 26.0 ± 7.6 years (15–50 years)
Body weight (mean ± SEM) (range) 58.0 ± 10.9 kg (40–128 kg)
Body height (mean ± SEM) (range) 164.7 ± 9.0cm (143–190 cm)
Loss of blood volume (mean ± SEM)
(range)
161.0 ± 145.5ml (4–1400 ml)
Migration length of bone fragments
(mean ± SEM) (range)
4.6 ± 2.7 mm (0–13 mm)
Duration of anesthesia (mean ± SEM)
(range)
187 ± 71 min (107–864 min)
Duration of surgery (mean ± SEM)
(range)
115 ± 45 min (66–750 min)
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http://www.molecularpain.com/content/9/1/34involved in the development of cerebral cavernous
malformations at the mRNA expression level. Addition-
ally, a high incidence of epilepsy is found in patients
with cerebral cavernous malformations [22], suggesting
the involvement of ZPLD1 in the nervous system.
ZPLD1 is also reportedly associated with childhood
obesity [23]. However, it is unclear whether ZPLD1 is as-
sociated with pain mechanism. According to the
HapMap database, the re2063640 SNP identified as a
candidate in the present study is located in a relatively
downstream region (approximately 4 kbp) that is close
to the ZPLD1 gene. This SNP may exert an effect on
the gene expression level of ZPLD1, but this needs to be
clarified in future studies.
The METTL4 gene is located on the chromosome region
18p11.32. Detailed information on the functions of its gene
product, however, is unavailable. No studies of which we
are aware have reported associations between METTL4
and specific diseases. Based on the molecular structure of
METTL4, it may affect methylation, which plays a major
role in various epigenetic regulatory mechanisms. DNA
methylation, recognized as the most common type of epi-
genetic modifications, is involved in gene silencing and
plays an important role in gene regulation, development,
and tumorigenesis. It has also been shown to be associated
with the pathophysiology of various nervous and mental
disorders. A mutation in MeCP2, a methyl-CpG binding
protein, reportedly causes Rett syndrome, characterized by
mental retardation and autism [24]. With regard to ac-
quired mental disorders, abnormal DNA methylation is
found in the brains of patients with schizophrenia and de-
pression. Using microarray technology, Mill et al. compre-
hensively analyzed DNA methylation in the frontal lobe in
patients with schizophrenia and bipolar (manic-depressive)
disorder and found changes in the DNA methylation of
genes involved in brain development and stress responses
[25]. According to the dbSNP database [26], the rs2677879
SNP, a candidate identified in the present GWAS of
nonsynonymous polymorphisms, leads to amino acid
substitution from Gln to Lys, likely causing functional
changes in the protein. Although the precise functions of
METTL4 are poorly understood, a representative METTL,
METTL11A, reportedly exhibited catalytic activity as a his-
tone methyltransferase [27]. Although future studies are
needed, the action of METTL4 might be involved in
methyltransferase activity and thus cause the methylation
of genomic DNA close to related genes, which could result
in the modulation of neural transmission related to sensory
disturbances.
The genes identified in the present study are different
from those previously reported to be associated with neuro-
pathic pain. Future studies that involve larger numbers of
patients may identify previously reported gene polymor-
phisms and determine the functional relationships betweenthe three gene polymorphisms identified as candidates in
the present study and peripheral neuropathy. We did not
consider the patients’ personalities (i.e., psychological fac-
tors) in the present study, which should be addressed in fu-
ture studies.
Conclusion
The present GWAS determined the onset of sensory dis-
turbances after BBSRO and identified three gene poly-
morphisms in or near the region of the ARIBD1, ZPLD1,
and METTL4 genes. Elucidating the relationship be-
tween neuropathic pain and genetic factors will elucidate
the risk factors for neuropathic pain in individual patients,
thereby allowing the selection of tailored treatments.
Methods
Patients
Enrolled in the study were 304 healthy patients (American
Society of Anesthesiologists Physical Status I; age, 15–50
years; 114 males and 190 females) who were scheduled to
undergo BSSRO for mandibular prognathism at Tokyo
Dental College Suidoubashi Hospital (Table 6). The study
protocol was approved by the Institutional Review Board,
Tokyo Dental College, Chiba, Japan, and the Institutional
Review Board, Tokyo Institute of Psychiatry (currently
Tokyo Metropolitan Institute of Medical Science), Tokyo,
Japan. Written informed consent was obtained from all of
the patients or parents when the patients were younger
than 20 years old and any accompanying image. Patients
who presented with distinct nerve injury during BSSRO
were excluded from the study.
Anesthesia and surgery
Four experienced, skilled surgeons were selected. These
surgeons were board-certified in the oral surgery specialty.
General anesthesia was induced with target-controlled in-
fusion (TCI) of propofol using a TCI pump (TE-371,
Terumo, Tokyo, Japan). Vecuronium (0.1 mg/kg) was ad-
ministered to facilitate nasotracheal intubation. After the
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pled for the preparation of DNA specimens. General
anesthesia was maintained with propofol at a target blood
concentration of 4–6 μg/ml. Vecuronium was adminis-
tered at a rate of 0.08 mg/kg/h. The lungs were ventilated
with oxygen-enriched air. Local anesthesia was performed
on the right side of the surgical field with 8 ml of 2% lido-
caine that contained 12.5 μg/ml epinephrine, and right
mandibular ramus osteotomy was performed. Local
anesthesia was then performed on the left side, and left
mandibular ramus osteotomy was performed. The bilat-
eral mandibular bone segments were fixed in appropriate
positions (Figure 3). Whenever systolic blood pressure or
heart rate exceeded +20% of the preinduction value during
surgery, intravenous (i.v.) fentanyl (1 μg/kg) was adminis-
tered. At the end of surgery, a rectal diclofenac sodium
suppository (50 mg) and dexamethasone (8 mg, i.v.) were
administered to prevent orofacial edema and postopera-
tive pain. Oral mecobalamin (1.5 mg/day) was adminis-
tered for 4 weeks after the operation.
Evaluation of sensory disturbances
Sensory disturbances were determined postoperatively
by the presence of hypoesthesia or dysesthesia in theFigure 3 Illustration of bilateral sagittal split ramus osteotomy, which
bone fragments.mental nerve area. Hypoesthesia was evaluated by
tactile-threshold tests 1 week after the operation. The 1
week time-point was chosen for assessment to avoid
testing during the time when postoperative pain was se-
vere. The tactile-threshold test was performed using a
Semmes-Weinstein pressure aesthesiometer (Research
Design, Houston, TX, USA; (Figure 4) [28]. The
Semmes-Weinstein pressure aesthesiometer consisted of
20 filaments with different diameters. The end of each
filament was mounted into an individual Lucite rod. The
amount of force applied through the long axis of each
filament to achieve a noticeable bend was determined.
The magnitude of these forces ranged from 0.0045 g to
447 g. This test was performed by two experienced
dentists.
Touch stimulation was performed using the method of
Bell [29]. The Semmes-Weinstein pressure aesthesiometer
was perpendicularly lowered to a test region for 1–1.5 s
and then lifted for 1–1.5 s. Stimulation was applied three
times with 1.65-4.08 manufacturer’s filament marking and
calculated force (Fmg) and once with 4.17-6.65 Fmg at
each point. All of these filaments, with the exception of
the largest (6.65 Fmg), bent when they reached the speci-
fied pressure. Stimulation began with the 1.65 Fmgsagittally splits the mandibular ramus into inside and outside
Figure 4 Photograph of Semmes-Weinstein pressure aesthesiometer test, which consists of 20 individual filaments with varying
diameters. These filaments are mounted into individual Lucite rods.
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force was increased until the patient perceived the stimu-
lation. Tactile sensitivity was recognized to be positive
when the patient perceived any stimulation, even if
the stimulation was not perceived as a normal tactile
sensation.
Based on the running courses of the labial inferior
ramification and mental ramification, measurements
were performed at two points [3]: (1) the vermilion
border at one-third the distance between the oral angles
and (2) the midpoint of the perpendicular line from
point (1) to the lower margin of the mentum.
The worst among the values obtained at the four
total test-points on both sides was regarded as the
representative value. This value was evaluated by the
interpretation scale reported by Bell [29]. In this
scale, sensory function is classified into five grades.
In the present study, the patients who were classified
into grades that were worse than the second grade
(2.83 Fmg) were regarded as hypoesthesic.
A patient who spontaneously recognized any ab-
normal sensations was regarded as dysesthesic. The
evaluation of dysesthesia was based on the definition
of the International Association for the Study of
Pain. Subjective symptoms were assessed by inter-
view 4 weeks after the operation. The patients were
asked to select words from the McGill Pain Ques-
tionnaires [30] to describe their pain (i.e., temporal,
brightness, thermal, dullness, traction pressure, con-
strictive pressure, etc.). The time-point of 4 weeks
was chosen for assessment to avoid testing during
the time of Wallerian [31] degeneration and retro-
grade degeneration after nerve damage.Whole-genome genotyping
Genomic DNA was extracted from whole-blood samples
using standard procedures. The extracted DNA was
dissolved in TE buffer (10 mM Tris–HCl and 1 mM
ethylenediaminetetraacetic acid, pH 8.0). The DNA con-
centration was adjusted to 100 ng/μl using a NanoDrop
ND-1000 Spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA).
Whole-genome genotyping was performed using
Infinium assay II utilizing an iScan system (Illumina)
according to the manufacturer’s instructions, with a total
of 361 samples including those of the patients enrolled in
the study. Genotyping was conducted basically the same
way as a previous report [32]. Five kinds of BeadChips were
used for genotyping 40, 67, 6, 120, and 128 samples,
respectively: HumanHap300 (total markers: 317,503),
HumanHap300-Duo (total markers: 318,237), Human610-
Quad v1 (total markers: 620,901), Human1M v1.0 (total
markers: 1,072,820), and Human 1M-Duo v3 (total
markers: 1,199,187). Some BeadChips include a number of
probes that are specific to copy number variation markers,
but most were for SNP markers on the human autosome
or sex chromosome. Approximately 300,000 SNP markers
were commonly included in all of the BeadChips.
Quality control
The data for the genotyped samples were analyzed using
BeadStudio or GenomeStudio with the Genotyping mod-
ule v3.3.7 (Illumina) to evaluate the quality of the results.
The genotype data from all five of the BeadChips were
merged to analyze all of the samples simultaneously (i.e.,
only the markers common to all of the BeadChips were
included in the analysis, and the others were automatically
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a genotype call rate of less than 0.95 were excluded from
further analyses. Markers with a genotype call frequency
of less than 0.95, “Cluster sep” (i.e., an index for genotype
cluster separation) of less than 0.1, and minor allele fre-
quencies of less than 0.05 were excluded from the subse-
quent association study.
Statistical analysis
Prior to the GWAS, associations between the clinical
data and hypoesthesia or dysesthesia expression fre-
quency after BSSRO were analyzed. Clinical data in-
cluded gender, age, body weight, body height, loss of
blood volume, migration length of bone fragments, dur-
ation of anesthesia, and duration of surgery (Table 6). A
logistic regression analysis was performed using SPSS
(12.0J for Windows, SPSS Japan, Tokyo, Japan).
The Fisher’s exact test was performed for all of the
genotype frequency data to investigate the deviation of
the distributions from those in the theoretical Hardy-
Weinberg equilibrium, which sometimes reflects geno-
typing errors or population stratification of the samples.
Markers with P values (df = 1) greater than approxi-
mately 2 × 10-7 (0.05/300,000) were considered for the
GWAS.
A multistage GWAS was conducted for the patients
who underwent painful cosmetic surgery to investigate
the association between genetic variations and sensory
disturbances after BSSRO. Among 361 subjects, one
subject did not meet the quality control criteria in our
preliminary analysis, and 57 and 58 subjects lacked clin-
ical data for hypoesthesia and dysesthesia, respectively.
Therefore, genotype data for a total of 360 subjects were
used for our three-stage GWAS (120 subjects for each of
the first-, second-, and final-stage analyses). Clinical data
for a total of 304 and 303 subjects were used for our
three-stage GWAS of hypoesthesia (104, 98, and 102
subjects for the first-, second-, and final-stage analyses,
respectively) and dysesthesia (105, 96, and 102 subjects
for the first-, second-, and final-stage analyses, respect-
ively), respectively. The subjects were recruited within
several years and randomly categorized into three inde-
pendent groups to minimize bias in the clinical data, in-
dicating that the samples and clinical data were not used
in chronological order for our first-, second-, and final-
stage analyses. In our preliminary analysis that used
merged markers between different BeadChips with
BeadStudio or GenomeStudio, 295,036 SNPs (including
6,016 nonsynonymous SNPs) were selected for the
analyses.
For the GWAS, the Cochran-Armitage trend test was
performed to explore markers that might confer suscep-
tibility to hypoesthesia evaluated by the Semmes-
Wemstem pressure aesthesiometer test or dysesthesiaafter BSSRO. The patients were divided into two groups
based on the presence or absence of symptoms, and a
linear trend analysis of the increased rate of subjects
with an increased number of variant risk alleles was
performed for all markers. Moreover, dominant and re-
cessive genetic models for each minor allele were used
for the analyses because of the previously insufficient
knowledge about the genetic factors associated with sen-
sory disturbances after BSSRO. The association study in-
cluded both female and male subjects for autosomal
markers, although male genotypes were excluded from
the analysis of X chromosome markers. All of the statis-
tical analyses were performed using gPLINK v. 2.050,
PLINK v. 1.07 PLINK [33], and Haploview v. 4.1 [34].
Single-nucleotide polymorphism annotations were cre-
ated based on an annotation file within Human 1M-Duo
v3 supplied by the manufacturer of the BeadChips. For
calculation of Q-values, SFDR (Stratified False Discovery
Rate) software [35] or PLINK v. 1.07 was used. Power
analyses were performed using G*Power v. 3.0.5 [36].
The GWAS procedure is summarized in the Additional
file 1: Figure S1 and Additional file 2: Figure S2. In the
first-stage analysis of 104 and 105 subjects for hypoesthesia
and dysesthesia, respectively, the SNPs that had statistical
P values of less than 0.05 were selected as the candidate
SNPs for the second-stage analysis among the SNP that
passed the quality control criteria within the 295,036
SNPs (6,016 nonsynonymous SNPs). For these SNPs,
the second-stage analysis was conducted. Again, the
SNPs that had P values of less than 0.05 were consid-
ered potential candidates and selected for further final-
stage analysis. Linkage disequilibrium (LD)-based SNP
pruning was also conducted in this stage utilizing
PLINK v. 1.07 software, and SNPs that were in approxi-
mate linkage equilibrium with an SNP were excluded
based on the following process: (i) consider a window
of 50 SNPs, (ii) calculate LD between each pair of SNPs
in the window, (iii) remove one of a pair of SNPs if the
LD is greater than 0.8, and (iv) shift the window five
SNPs forward and repeat the procedure. In the final
stage, the association study was conducted to determine
whether the possible associations between the SNPs se-
lected in the second stage and phenotypic traits would
be strictly replicated. In this stage, the Q values of the
false discovery rate were calculated to correct for mul-
tiple testing, in addition to P values based on previous
reports [37,38]. The SNPs with Q < 0.05 in the analysis
were considered genome-wide significant.
Two independent patterns of the GWAS were con-
ducted to effectively explore candidate SNPs that
showed statistically strong association with the pheno-
typic traits and those that could functionally impact
neighboring genes. In the first pattern, a normal GWAS
procedure targeted all of the SNPs that were available
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GWAS procedure targeted only nonsynonymous SNPs
that tended to affect the function of the protein encoded
by the relevant gene (Additional file 2: Figure S2).
A log quantile-quantile (QQ) P-value plot as a result
of the GWAS for the combined samples was subse-
quently drawn to check the pattern of the generated
P-value distribution, in which the observed P values
against the values expected from the null hypothesis of
uniform distribution, calculated as –log10 (P value),
were plotted for each model. Many of the plots were
mostly concordant with the expected line (y = x), espe-
cially over the range of 0 < −log10 (P value) < 4, indicat-
ing no apparent population stratification of the samples
used in the study, although the plots for the recessive
model, especially for hypoesthesia, apparently deviated
over the range of –log10 (P value) > 3 (Additional file 4:
Figure S3 and Additional file 5: Figure S4).Additional files
Additional file 1: Figure S1. Schematic illustration of the multistage
GWAS that targeted all of the SNPs that were available. Potent candidate
SNPs associated with (A) hypoesthesia evaluated by the Semmes-
Weinstein pressure aesthesiometer test and (B) dysesthesia after BSSRO
were selected for the three-stage GWAS.
Additional file 2: Figure S2. Schematic illustration of the multistage
GWAS that targeted only nonsynonymous SNPs. Potent candidate SNPs
associated with (A) hypoesthesia evaluated by the Semmes-Weinstein
pressure aesthesiometer test and (B) dysesthesia after BSSRO were
selected for the three-stage GWAS.
Additional file 3 Table S1. Frequencies of hypoesthesia in patients with
the ARID1B (rs502281) genotype. Table S2 Frequencies of hypoesthesia
in patients with the ZPLD1 (rs2063640) genotype. Table S3 Frequencies
of dysesthesia in patients with the METTL4 (rs2677879) genotype.
Additional file 4: Figure S3. Log quantile-quantile (QQ) P value plot for
all of the samples as a result of the GWAS for hypoesthesia evaluated by
the Semmes-Weinstein pressure aesthesiometer test after BSSRO in
(A) trend, (B) dominant, and (C) recessive models.
Additional file 5: Figure S4. Log quantile-quantile (QQ) P value plot for
all of the samples as a result of the GWAS for dysesthesia after BSSRO in
(A) trend, (B) dominant, and (C) recessive models.Abbreviations
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